You are here: Industry Insights > CLL

News List

NICE backs AZ' Calquence for chronic lymphocytic leukaemia pharmatimes
December 09, 2020
The National Institute for Health and Care Excellence has published preliminary guidelines backing use of AstraZeneca's Calquence (acalabrutinib) as an NHS funded treatment for chronic lymphocytic leukaemia (CLL).
NICE recommends new chemo-free chronic lymphocytic leukaemia treatment europeanpharmaceuticalreview
November 16, 2020
More than 1,000 people each year could benefit from treatment with a combination of venetoclax and obinutuzumab, according to NICE.
AbbVie’s Venclyxto gets NICE blood cancer backing pharmatimes
November 12, 2020
AbbVie’s Venclyxto (venetoclax) has been recommended for use by the National Institute of Health and Care Excellence (NICE) as a routine treatment for chronic lymphocytic leukaemia (CLL).
EU OK for AZ’s Calquence in CLL pharmatimes
November 11, 2020
The European Commission has approved AstraZeneca’s Calquence (acalabrutinib)for the treatment of adult patients with chronic lymphocytic leukaemia (CLL).
Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab pharmaceutical-business-review
September 23, 2020
Janssen Pharmaceutical, part of Johnson & Johnson, has secured approval from the European Commission (EC) for expanded use of Imbruvica (ibrutinib) in combination with rituximab for previously untreated adult patients with chronic lymphocytic leukaemia.
Ascentage Pharma’s Bcl-2 inhibitor APG-2575 granted orphan drug Designation by FDA to treat chronic lymphocytic leukaemia pharmaceutical-business-review
September 23, 2020
Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) ...
EU expands scope of Imbruvica to include untreated CLL patients pharmatimes
September 17, 2020
The European Commission (EC) has expanded the marketing authorisation for Janssen's Imbruvica (ibrutinib) to include treatment naïve patients with chronic lymphocytic leukaemia (CLL).
Janssen gets EC approval for expanded use of IMBRUVICA (ibrutinib) plus rituximab to treat CLL expresspharma
September 08, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has approved a variation to the marketing authorisation for IMBRUVICA (ibrutinib) ...
Calquence Recommended for CHMP Approval for Chronic Lymphocytic Leukemia americanpharmaceuticalreview
July 31, 2020
AstraZeneca’s Calquence (acalabrutinib) has been recommended for marketing authorization in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults.
Janssen gets CHMP positive opinion for expanded use of IMBRUVICA, rituximab combo in CLL pharmaceutical-business-review
July 29, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for IMBRUVICA ...

Previous page 1 2 3 4 Next page